Is Acrivon Therapeutics, Inc. Common Stock (ACRV) a Buy, Sell, or Hold?
Acrivon Therapeutics, Inc. Common Stock
NASDAQ:ACRV
$2.13 USD
$0.15 (7.58%)
- Volume
- 1.02M
- Average Volume
- 577.41K
- Market Capitalization
- $67.21M
- P/E Ratio
- -1.07
- Dividend Yield
- 0.00%
- Price Target
- $20.00
- Year High
- $3.56
- Year Low
- $1.20
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $8.98
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Peter Blume-Jensen |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ACRV |
| CUSIP | 004890109 |
| CIK | 0001781174 |
| Web | https://www.acrivon.com |
| Phone | 617-207-8979 |
| Currency | USD |
| Employees | 75 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.03 |
| Payout Ratio | 0.00 |
| Current Ratio | 8.98 |
| Quick Ratio | 8.98 |
| Cash Ratio | 3.08 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -1.71 |
| Price / Cash Flow | -1.01 |
| Price / Book | 0.86 |
Price Target and Rating
| Average Stock Price Forecast | $20.00 |
| High Stock Price Forecast | $30.00 |
| Low Stock Price Forecast | $17.00 |
| Forecast Upside/Downside | -89.35% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 10 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-2.02 |
| Trailing P/E Ratio | -1.07 |
| PEG Ratio | -0.10 |
| P/E Growth | -0.10 |
| Net Income | $-77.9M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -64.43% |
| Return on Assets | -71.65% |
Financials Score
| AltmanZ Score | -2.33 |
| Piotroski Score | 1.00 |
| Working Capital | 88.17M |
| Total Assets | 107.83M |
| Ebit | -83.48M |
| Market Cap | 62.8M |
| Total Liabilities | 12.32M |
Poll Results
About Acrivon Therapeutics, Inc. Common Stock (NASDAQ:ACRV) Stock
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a p ... otentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
Acrivon Therapeutics: Priced For Failure, Built For Precision
2026-07-13 04:44:48
Acrivon Therapeutics (ACRV) trades below cash value, with the market deeply discounting its platform and pipeline despite promising early data. ACRV's AP3 platform enables precision patient-matching for kinase inhibitor therapies, showing a 50% response rate in serous endometrial cancer with ACR-368. Key near-term catalysts include Phase 2b ACR-368 data and Phase 1 ACR-2316 expansion results, both critical for de-risking and expanding commercial potential.
Acrivon Therapeutics to Present at TD Cowen's 7th Annual Oncology Innovation Summit
2026-05-21 07:30:00
WATERTOWN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced the company's president and chief executive officer, Peter Blume-Jensen, M.D.
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-05-15 16:00:00
WATERTOWN, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced that the company approved a grant of equity award under its 2023 Inducement Plan to one employee. The equity award was granted in the form of stock options and has a grant date of May 15, 2026.
2026-05-13 16:10:00
The registrational intent ACR-368 Phase 2b study is advancing with a prespecified simultaneous interim analysis and data update for both all-comer (biopsy-independent) serous endometrial cancer arms in second half 2026
2026-04-17 16:00:00
Potent preclinical efficacy with durable immune memory observed in combinations of either ACR-368 or ACR-2316 with anti-PD-L1 and strong synergy of ACR-368 with Topoisomerase 1 (Topo 1) inhibition
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-04-15 16:05:00
WATERTOWN, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced that the company approved a grant of equity award under its 2023 Inducement Plan to one employee. The equity award was granted in the form of stock options and has a grant date of April 15, 2026.
Frequently Asked Questions
-
What is the current Acrivon Therapeutics, Inc. Common Stock (ACRV) stock price?
-
Acrivon Therapeutics, Inc. Common Stock(NASDAQ:ACRV) stock price is $2.13 in the last trading session. During the trading session, ACRV stock reached the peak price of $3.56 while $1.2 was the lowest point it dropped to. The percentage change in ACRV stock occurred in the recent session was 7.58% while the dollar amount for the price change in ACRV stock was $0.15.
-
ACRV's industry and sector of operation?
-
The NASDAQ listed ACRV is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ACRV?
-
Adam D. Levy | Chief Financial Officer & Principal Financial Officer
Eric J. Devroe | Chief Operating Officer
Jesper V. Olsen | Academic Co-Founder, Head of Phosphoproteomics & Member of Scientific Advisory Board
Bruce Close | Vice President of Quality & Compliance
Erick Gamelin | Chief Development Officer -
How many employees does ACRV have?
-
Number of ACRV employees currently stands at 75. ACRV operates from 480 Arsenal Way, Watertown, MA 02472, US.
-
Link for ACRV official website?
-
Official Website of ACRV is: https://www.acrivon.com
-
How do I contact ACRV?
-
ACRV could be contacted at phone #617-207-8979 and can also be accessed through its website. ACRV operates from 480 Arsenal Way, Watertown, MA 02472, US.
-
How many shares of ACRV are traded daily?
-
The average number of ACRV shares traded daily for last 3 months was 577.41K.
-
What is the market cap of ACRV currently?
-
The market value of ACRV currently stands at $67.21M with its latest stock price at $2.13